• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine (NQ: EDIT )

    6.040 +0.530 (+9.62%)
    Streaming Delayed Price Updated: 11:05 AM EDT, May 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Editas Medicine

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    A Preview Of Editas Medicine's Earnings
    Via Benzinga
    Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
    This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
    Via Benzinga
    Analyst Ratings for Editas Medicine
    Via Benzinga
    Is Editas Stock a Buy Now?
    Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now? 
    Via The Motley Fool
    Expert Ratings for Editas Medicine
    Via Benzinga
    3 Gene Editing Stocks to Generate Super-Charged Gains
    As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
    Via Benzinga
    1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
    Both are in a race against time to commercialize a medicine before cash runs out. 
    Via The Motley Fool
    Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
    Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
    Via Benzinga
    Analyst Expectations for Editas Medicine's Future
    Via Benzinga
    Expert Ratings for Editas Medicine
    Via Benzinga
    Is Editas Medicine Stock a Buy Now?
    The fortunes of this once-promising biotech company have changed in the past year. 
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
    Via InvestorPlace
    NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
    Via Benzinga
    Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
    It's key to understand the resources it will take to deliver a company's pipeline. 
    Via The Motley Fool
    Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
    The better of the pair should be able to beat Bluebird Bio. 
    Via The Motley Fool
    Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
    Via Benzinga
    Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
    Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
    Via Benzinga
    Why Editas Medicine Stock Is Soaring Today
    Investors are cheering a big analyst upgrade for the gene-editing stock. 
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
    Via Benzinga
    Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
    Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market... 
    Via Benzinga
    Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
    U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
    Via Benzinga
    1 Gene Editing Stock to Buy Now, and 1 to Sell
    Target markets matter. So does having the cash to get to them. 
    Via The Motley Fool
    These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
    Is the Street's optimism justified here? 
    Via The Motley Fool
    This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
    Reaching profitability could be harder than investors expect. 
    Via The Motley Fool
    Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
    Via Benzinga
    What Is CRISPR And Why Should Your Portfolio Care?
    CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
    Via Talk Markets
    After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
    It's not about to start making money anytime soon. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.